La cadena de opciones muestra datos clave de las opciones de acciones de FibroGen a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para FibroGen..

FibroGen (NASDAQ:FGEN) Bolsa, Cadena de Opciones

FIBROGEN INC

FibroGen

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Konskie,,Poland,-,March,08,,2025:,Restoration,Hardware,Company,Logo

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADBE

BIAF

CGBS

EONR

FGEN

GNLN

HCTI

HUSA

INDO

NINE

PRZO

RNTX

RSLS

SBET

TPET

TRAW

USEG

VEON

RH sorprende con ganancias positivas en el primer trimestre y mantiene su guía para 2025, mientras sus acciones suben un 18,2 %.

Las acciones de RH se disparan un 18%; Aquí están 20 acciones que se mueven antes de la apertura del mercado

AdobeStockholm,,Sweden,-,July,26,,2021:,A,Wall,Sign,For

ZDGE

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: ADBE, MNY, RH, FGEN y ZDGE.

5 acciones en el foco este viernes: ADBE, MNY, RH, FGEN y ZDGE

FibroGen Inc

Press Releases

FibroGen to Report First Quarter 2025 Financial Results

Earnings

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Management

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

FibroGen Announces 1-for-25 Reverse Stock Split

FibroGen to Report Second Quarter 2025 Financial Results

FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Contracts

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Annovis Bio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

BioAtla

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Elutia

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

INmune Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Medicus Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PepGen

Plus Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Lunai Bioworks

RenovoRx

Serina Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

HC Wainwright & Co.

B of A Securities

Goldman Sachs

Stifel

Comments

FibroGen

FibroGen (FGEN) Opciones

FibroGen (NASDAQ:FGEN) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL